Investing.comQwen · 实盘不做把握 3/10不做原因:无增量信息
北京时间·🕒 发布 19:04:34·⟳ 抓取 19:11:58 +7m24s·⚡ 决策 08-28 19:13:00 +1m02s·59.8 天前
United Therapeutics将在ESC与ERS大会上展示ralinepag及雾化treprostinil的III期临床数据
本次公告是学术会议展示日程安排，核心临床数据(ADVANCE OUTCOMES ralinepag III期、TETON雾化treprostinil III期)此前已公布，NDA已于2026年6月提交。公告未披露新的数据结果、金额或监管进展，不构成新增催化。此外美股当前处于盘前时段，无法执行交易。
📄 原文Investing.com↗ 原文
United Therapeutics to present drug trial data at conferences
Warsh, Nvidia And oil In focus - what’s moving markets SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. - United Thera…
不做 United Therapeutics（UTHR.US）
学术会议展示日程公告，核心临床数据(ADVANCE OUTCOMES、TETON)已公布，NDA已于2026年6月提交，本次无新增数据或监管进展，不构成新催化；且美股当前盘前不可成交，数据展示跨越多日无单一催化时点
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
United Therapeutics宣布在ESC和ERS大会上展示8项报告，但所有核心数据(ADVANCE OUTCOMES、TETON、ARTISAN)均为已公布结果的会议展示安排，NDA已于6月提交，本次公告无新增数据、无金额、无监管状态变化，属于学术会议日程公告而非新催化。
🔎 新鲜度:最早出现 2026-08-28 · 扩散 low · price-in 风险 high ↗
原文全文
展开原文 · 1,986 字
Warsh, Nvidia And oil In focus - what’s moving markets
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. - United Therapeutics Corporation (NASDAQ:UTHR) announced today it will present eight presentations at the European Society of Cardiology Congress 2026 in Munich from August 28-31 and the European Respiratory Society Congress 2026 in Barcelona from September 5-9, according to a press release statement.
The presentations include analyses from the phase 3 ADVANCE OUTCOMES study of investigational ralinepag in pulmonary arterial hypertension, the phase 3 TETON clinical program evaluating nebulized treprostinil in idiopathic pulmonary fibrosis, and the ARTISAN study evaluating parenteral treprostinil in PAH.
Data from ADVANCE OUTCOMES shows ralinepag achieved clinical improvement in a lower risk PAH population and reduced clinical worsening in PAH patients with connective tissue disease. TETON analyses indicate nebulized treprostinil improved lung function and reduced serious clinical worsening events in IPF patients.
The company will also present interim data from the ARTISAN study showing early and rapid treprostinil titration improved right ventricular ejection fraction at 12 months in PAH patients. Preliminary data from PHINDER, a study designed to improve screening for pulmonary hypertension associated with interstitial lung disease, will also be presented.
In June 2026, United Therapeutics submitted a New Drug Application for ralinepag to treat PAH and a supplemental New Drug Application for nebulized treprostinil to treat IPF to the FDA. Ralinepag has not been approved for use in any indication by the FDA and remains investigational for PAH. Nebulized treprostinil remains investigational for IPF.
The presentations will include four oral presentations and four poster presentations across the company’s commercial and development portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. - United Therapeutics Corporation (NASDAQ:UTHR) announced today it will present eight presentations at the European Society of Cardiology Congress 2026 in Munich from August 28-31 and the European Respiratory Society Congress 2026 in Barcelona from September 5-9, according to a press release statement.
The presentations include analyses from the phase 3 ADVANCE OUTCOMES study of investigational ralinepag in pulmonary arterial hypertension, the phase 3 TETON clinical program evaluating nebulized treprostinil in idiopathic pulmonary fibrosis, and the ARTISAN study evaluating parenteral treprostinil in PAH.
Data from ADVANCE OUTCOMES shows ralinepag achieved clinical improvement in a lower risk PAH population and reduced clinical worsening in PAH patients with connective tissue disease. TETON analyses indicate nebulized treprostinil improved lung function and reduced serious clinical worsening events in IPF patients.
The company will also present interim data from the ARTISAN study showing early and rapid treprostinil titration improved right ventricular ejection fraction at 12 months in PAH patients. Preliminary data from PHINDER, a study designed to improve screening for pulmonary hypertension associated with interstitial lung disease, will also be presented.
In June 2026, United Therapeutics submitted a New Drug Application for ralinepag to treat PAH and a supplemental New Drug Application for nebulized treprostinil to treat IPF to the FDA. Ralinepag has not been approved for use in any indication by the FDA and remains investigational for PAH. Nebulized treprostinil remains investigational for IPF.
The presentations will include four oral presentations and four poster presentations across the company’s commercial and development portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。